Repositório Digital

A- A A+

Philadelphia-negative chronic myeloproliferative neoplasms

.

Philadelphia-negative chronic myeloproliferative neoplasms

Mostrar registro completo

Estatísticas

Título Philadelphia-negative chronic myeloproliferative neoplasms
Autor Bittencourt, Rosane Isabel
Vassallo, Jose
Chauffaille, Maria de Lourdes Lopes Ferrari
Xavier, Sandra Guerra
Pagnano, Katia Borgia Barbosa
Nascimento, Ana Clara Kneese Virgilio do
Souza, Cármino Antônio de
Chiattone, Carlos Sérgio
Abstract Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on morphological, cytogenetic and molecular features. In 2005, the identification of a recurrent molecular abnormality characterized by a gain of function with a mutation in the gene encoding Janus kinase 2 (JAK2) paved the way for greater knowledge of the pathophysiology of myeloproliferative neoplasms. The JAK2 mutation is found in 90-98% of polycythemia vera and in about 50% essential thrombocytosis and primary myelofibrosis. In addition to the JAK2 mutation, other mutations involving TET2 (ten-eleven translocation), LNK (a membrane-bound adaptor protein); IDH1/2 (isocitrate dehydrogenase 1/2 enzyme); ASXL1 (additional sex combs-like 1) genes were found in myeloproliferative neoplasms thus showing the importance of identifying molecular genetic alterations to confirm diagnosis, guide treatment and improve our understanding of the biology of these diseases. Currently, polycythemia vera, essential thrombocytosis, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia and mastocytosis are included in this group of myeloproliferative neoplasms, but are considered different situations with individualized diagnostic methods and treatment. This review updates pathogenic aspects, molecular genetic alterations, the fundamental criteria for diagnosis and the best approach for each of these entities.
Contido em Revista Brasileira de Hematologia e Hemoterapia. São Paulo. vol. 34, n.2 (2012), p. 140-149
Assunto Mielofibrose primária
Policitemia vera
Transtornos mieloproliferativos
Trombocitose
[en] Myeloproliferative disorders
[en] Polycythemia vera
[en] Primary myelofibrosis
[en] Thrombocytosis
Origem Nacional
Tipo Artigo de periódico
URI http://hdl.handle.net/10183/94911
Arquivos Descrição Formato
000876684.pdf (1.281Mb) Texto completo Adobe PDF Visualizar/abrir

Este item está licenciado na Creative Commons License

Este item aparece na(s) seguinte(s) coleção(ões)


Mostrar registro completo

Percorrer



  • O autor é titular dos direitos autorais dos documentos disponíveis neste repositório e é vedada, nos termos da lei, a comercialização de qualquer espécie sem sua autorização prévia.
    Projeto gráfico elaborado pelo Caixola - Clube de Criação Fabico/UFRGS Powered by DSpace software, Version 1.8.1.